methyl 2-(p-nitrophenyl)methyleneacetoacetate | 184681-54-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl 2-(p-nitrophenyl)methyleneacetoacetate
• 英文别名: methyl 2-(p-nitrobenzylidene)acetoacetate；2-[(4-nitrophenyl)methylene]-3-oxobutanoic acid, methyl ester；2-[(4-nitrophenyl)methylene]-3-oxobutanoic acid,methyl ester；methyl 2-(4-nitrobenzylidene)-acetoacetate；NQ3X6M47R7；methyl (2Z)-2-[(4-nitrophenyl)methylidene]-3-oxobutanoate
• CAS: 184681-54-7
• 化学式: C₁₂H₁₁NO₅
• 分子量: 249.223
• InChiKey: BEOJAFGZPXTLGC-XFFZJAGNSA-N

物化性质

• 熔点：
  110-114 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  367.8±27.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  89.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(p-nitrophenyl)methyleneacetoacetate 在 盐酸 、 ammonium acetate 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 生成 (2S,4S)-6-Methyl-2,4-bis-(4-nitro-phenyl)-3-nitroso-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester
  参考文献：
  名称：

  Goerlitzer; Heinrici; Ernst, Pharmazie, 1999, vol. 54, # 1, p. 35 - 41

  摘要：

  DOI：
• 作为产物：
  描述：

  对硝基苯甲醛 、 乙酰乙酸甲酯 、 乙腈 在 三氯化铁 乙酰氯 作用下， 以82%的产率得到methyl 2-(p-nitrophenyl)methyleneacetoacetate
  参考文献：
  名称：

  氯化铁（III）催化方便地一锅合成β-乙酰氨基羰基化合物

  摘要：

  乙醛，可烯醇化的酮或1,3-二羰基化合物，乙腈/苄腈和乙酰氯的一锅多组分反应描述了一种温和，廉价的方法，用于使用FeCl 3 ·6H 2 O制备β-乙酰胺基羰基化合物。，以及高效的催化剂。还说明了底物以及取代基对于多组分反应与Knoevenagel缩合的影响。该方法的主要特点是操作简便，反应条件温和且收率高。

  DOI：

  10.1016/j.tet.2007.04.019

文献信息

• Antihypertensive 1,5-benzothiazepine derivatives, compositions, and
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04654335A1

  公开（公告）日：1987-03-31

  Compounds of formula ##STR1## wherein X is S or SO.sub.2, R.sub.4 is aryl or hetero, and R.sub.1 is hydrogen or ##STR2## are disclosed. These compounds are useful as cardiovascular agents and especially as anti-hypertensive agents.

  公式为##STR1##的化合物中，其中X是S或SO.sub.2，R.sub.4是芳基或杂原子基，R.sub.1是氢或##STR2##。这些化合物可用作心血管药物，特别是抗高血压药物。
• Regioselective synthesis of pyridines and dihydropyridines derived from β-amino acids and aminophosphonates by reaction of N-vinylic phosphazenes with α,β-unsaturated ketones
  作者：Francisco Palacios、Esther Herrán、Gloria Rubiales、Concepción Alonso

  DOI：10.1016/j.tet.2007.03.146

  日期：2007.6

  Reaction of N-vinylic phosphazenes with α,β-unsaturated ketones leads to the formation of pyridines derived from β-amino acids in a regioselective fashion. The use of functionalized enones derived from α-acylstyryl-carboxylates or -phosphonates affords biologically active asymmetrical and symmetrical dihydropyridines substituted with carboxylate or phosphonate groups including nitrendipine, felodipine

  的反应Ñ与α-vinylic磷腈，β不饱和酮导致吡啶的形成从β氨基酸在一个区域选择性的方式得到。使用衍生自α-酰基苯乙烯基-羧酸酯或-膦酸酯的官能化烯酮提供了被羧酸酯或膦酸酯基团取代的生物活性不对称和对称二氢吡啶，包括硝苯地平，非洛地平，MRS 1097和依诺地平类似物。
• DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
  申请人：——

  公开号：US20030082623A1

  公开（公告）日：2003-05-01

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

  这项发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，包括编码人类MCH1受体的孤立核酸的载体，包含这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，互补于编码人类MCH1受体独特序列的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，孤立人类MCH1受体的分离方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。这项发明提供了一种修改受试者摄食行为的方法，包括向受试者投与足以减少受试者体重和/或减少受试者食物摄入量的MCH1拮抗剂的量。这项发明还提供了一种治疗患有抑郁和/或焦虑的受试者的方法，包括向受试者投与足以治疗受试者抑郁和/或焦虑的MCH1拮抗剂的量。
• Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
  申请人：——

  公开号：US20030069261A1

  公开（公告）日：2003-04-10

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

  这项发明涉及选择性拮抗黑素浓集激素-1（MCH1）受体的化合物。该发明提供了一种包括所述化合物的治疗有效量和药学可接受载体的药物组合物。该发明提供了一种通过结合本发明化合物的治疗有效量和药学可接受载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学可接受载体。该发明还提供了一种修改受试者进食行为的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。该发明还提供了一种治疗受试者进食障碍的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。在该发明实施方式中，进食障碍可以是暴食症、暴食症神经质或肥胖症。
• [EN] DIHYDROPYRIMIDINES AND USES THEREOF<br/>[FR] DIHYDROPYRIMIDINES ET LEURS UTILISATIONS
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：WO1996014846A1

  公开（公告）日：1996-05-23

  (EN) This invention is directed to dihydropyrimidine compounds which are selective antagonists for human $g(a)1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where the antagonism of the $g(a)1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.(FR) Cette invention se rapporte à des composés dihydropyrimidine qui sont des antagonistes sélectifs pour les récepteurs $g(a)1C humains, ainsi qu'aux utilisations de ces composés dans la réduction de la pression intraoculaire, l'inhibition de la synthèse du cholestérol, le relâchement des tissus inférieurs des voies urinaires, le traitement de l'hyperplasie prostatique bénigne, l'impuissance, l'arythmie cardiaque et le traitement de toutes maladies pour lesquelles l'antagonisme du récepteur $g(a)1C peut être utile. L'invention se rapporte encore à une composition pharmaceutique comprenant une quantité thérapeutiquement efficace des composés définis ci-dessus et à un excipient pharmaceutiquement acceptable.

  这项发明涉及选择性拮抗人类$g(a)1C受体的二氢嘧啶化合物。该发明还涉及使用这些化合物降低眼内压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常以及治疗任何需要拮抗$g(a)1C受体的疾病。该发明还提供了一种制药组合物，包括上述定义的化合物的治疗有效量和药用载体。